Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

 Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

Shots:

  • The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial skin and skin structure infections (ABSSSI) respectively
  • OPTIC study results: ECR (81.1, vs 82.7%,); IACR @PTE (87.6%, vs 85.1%); TEAEs (6.0% vs 6.7%); OASIS-1 study: ECR (84.8% vs 85.5%); IACR @PTE (86.1% vs 83.6%); mortality rate (0.3% vs 0.6%)
  • Nuzyra (qd, IV/oral) is an antibiotic, targeted for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, also being evaluated in UTI & is approved by the US FDA for resistance diseases i.e CABP & ABSSSI

Click here read full press release/ article | Ref: Globe Newswire | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post